Navigation Links
bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool
Date:3/11/2010

DURHAM, N.C., March 11 /PRNewswire/ -- bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens. The product can be used as an aid to identify, prevent, and control VRE colonization in healthcare settings. Infections with these drug resistant organisms produce severe adverse events in patients.(www.biomerieux-usa.com/chromid)

According to the Centers for Disease Control and Prevention (CDC), VRE is spread from patient to patient via caregivers. A study published in Clinical Infectious Diseases in Oct. 2009 examined the hospital and societal costs of antimicrobial-resistant infections (ARIs) in a Chicago teaching hospital. According to the study, 31 percent of patients with antibiotic-resistant infections in the study had an infection due to VRE and 40 percent of these infections were healthcare associated.(1) In a publication by Carmeli et al., infections with these pathogens were reported to have significant impact on patient morbidity, mortality, length of stay, and total hospital costs:

  • Case fatality rate of 11% higher than normal patients
  • 6.6 days greater length of stay
  • $20,534 in additional hospital costs(2)

"We pioneered this chromogenic media for systematic and cost-efficient screening to control the spread of VRE infections, significant from both a medical and economic perspective," said Thierry Bernard, corporate vice president, Commercial Operations for bioMerieux. "As part of a comprehensive infection prevention program, chromID VRE can help institutions identify the reservoir and control the spread of these pathogenic organisms."  

chromID VRE is the latest screening tool added to the bioMerieux arsenal in the fight against healthcare-associated infections (HAIs). chromID VRE along with chromID™ MRSA, FDA cleared and introduced last fall, provide simple and cost-effective solutions in the fight against these bacterial pathogens. The presence of vancomycin-resistant enterococci on chromID VRE is visually identified by the presence of blue-to-green colonies with E. faecalis and violet-colored colonies with E. faecium after a 24- to 48-hour incubation period.

As a leader in microbiology, bioMerieux's objective is to provide customers with the most advanced and complete solution set to effectively manage infectious diseases such as VRE, spanning both manual and automated techniques. bioMerieux provides a more comprehensive approach to containing VRE and HAIs in general, by offering an integrated solution for HAIs which meets the needs of healthcare professionals in the three key areas of infection control:

  • Prevention: Patient screening and environmental monitoring
  • Surveillance: Information management (alerts, epidemiology studies, antibiotic monitoring)
  • Intervention: Diagnosis of HAI and outbreak management

Identifying resistance and helping clinicians get clear actionable information so they can begin effective antibiotic therapy as early as possible is an integral part of bioMerieux's S.M.A.R.T. Campaign (www.biomerieux-usa.com/smart). The Solutions to Manage the Antimicrobial Resistance Threat (S.M.A.R.T.) initiative promises to create more educational resources for the lab and to provide healthcare professionals with relevant tools to identify, monitor, prevent, and track resistance.

References:

1. Roberts R. et al. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clinical Infectious Disease 2009;49:1175-84.

2. Carmeli Y, et al. Health and Economic Outcomes of Vancomycin-Resistant Enterococci. Arch Intern Med. 2002 ;162:2223-2228.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached euro 1.223 billion with 85 percent of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux-usa.com.

SOURCE bioMerieux

Back to top
'/>"/>
SOURCE bioMerieux
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. bioMerieux Selects Brainware to Automate Accounts Payable
2. 2010 UNICEF Tap Project Launches to Help Provide Safe Water to Children Worldwide
3. Johns Hopkins Launches “Energy Policy and Climate” Master's Degree
4. National Asbestos Lawyers of Cooney Conway Launches Mesothelioma Portal
5. RememberItNow! Launches Mobile Medication Reminder and eHealth Service
6. Grand Opening of LIFE Ionizer Australia Launches with a Free Ionizer Upgrade with Purchase of Alkaline Water Ionizer from LIFE Ionizer Australia
7. New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com
8. The Chopra Center for Wellbeing Launches “Manifest the Life You Deserve”
9. Bick Group Launches Leveraging Cloud Computing Within the Modern Data Center Webinar Series
10. QuickMedical Launches Medical Equipment Lease Program With Providence Capital
11. Pregnancy Health Centre Launches Website to Help Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: